Study Companion: Answers to Clinicians’ Questions About Biosimilar Use in Inflammatory Conditions

To participate in this activity, please:

We have the answers, do you know the questions? If so, you’ll enjoy this Jeopardy style game focused on biosimilars. Biosimilar anti-rheumatologic disease modifying therapies have been approved by the FDA and are becoming increasingly available in the US. Yet, concerns among some clinicians and patients remain. In this activity, Jonathan Kay, MD, discusses the approval process and other issues related to biosimilar development and use so that you can be confident when discussing them with and prescribing them for your patients.

Editor’s Note: The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved applications.

Course Credit:

1.00 ACPE Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour

Dates:

Opens: 2022-04-30
Closes: 2023-04-30

Target Audience:

This activity was developed for rheumatologists, gastroenterologists, dermatologists, primary care physicians, along with nurse practitioners, physician assistants and pharmacists who manage patients who are candidates for a biosimilar therapy.

This activity is supported by an educational grant from Pfizer Inc.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #. This program is designated for up to 1.00 contact hour (0.1 CEUs) of continuing pharmacy education credit.
Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.00 contact hour may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.00 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Chris Fischer, MSc (Medical Writer)
No significant relationships to disclose.

Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Jonathan Kay, MD

    Timothy S. and Elaine L. Peterson Chair in Rheumatology
    Professor of Medicine and Population and Quantitative Health Sciences
    UMass Chan Medical School and UMass Memorial Medical Center
    Worchester, Massachusetts

Learning Objectives

  • Compare biosimilars with their reference products
  • Describe the FDA's stepwise, totality-of-the-evidence pathway for biosimilar development, including pharmacovigilance
  • Identify the regulatory and statutory requirements regarding biosimilar interchangeability and substitution
  • Develop strategies to discuss biosimilar risks and benefits with patients who are currently treated or considering treatment with a biologic

Faculty Disclosures

Jonathan Kay, MD

No relationships to disclose.